Of the 655 patients enrolled in this study, 89 (13.5%) (95% confidence interval [CI] 15%-10%) presented with unilateral exophthalmos. Exophthalmometer values in the ...

Batoclimab did not significantly improve proptosis responder rates vs placebo in patients with thyroid eye disease at week 24. Topline data were announced from two phase 3 trials evaluating batoclimab ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...

Dr. Mark A. Matza (Medicine): An 18-year-old man was evaluated at this hospital because of diplopia and proptosis of the left eye. The patient had been well until approximately 33 months before this ...

Please provide your email address to receive an email when new articles are posted on . Of adults receiving elegrobart every 4 weeks, 50% had a decrease in proptosis at 24 weeks compared with 15% of ...

Please provide your email address to receive an email when new articles are posted on . A 49-year-old man was transferred to the University of New Mexico Health Sciences Center after a helmeted ...

Background The purpose of this retrospective follow-up study is to evaluate the prevalence of patients with thyroid eye disease presenting with apparent unilateral proptosis and determine the ...